

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Harrington et al.

Serial No.: 08/951,733

Filed: October 16, 1997

For: Novel Genes Encoding Telomerase Proteins

Docket No.: A-433B



Group Art Unit No.: 1634

Examiner: N/A

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231RECEIVED
JUN 2 1998
MAIL ROOM
SERIALS CENTER

Sir:

As a means of complying with the duty of disclosure, Applicants submit a "List of References Cited by Applicant" on a modified PTO-1449 form and provide a copy of each of the listed references for consideration by the Examiner with the following exception:

EO Oral Presentations at Cold Spring Harbor Laboratory Conference on Telomeres and Telomerase, Cold Spring Harbor, NY, USA, November 3-6, 1996. This is a relevant public disclosure, but no written document is available.

Only tables of contents have been provided on the following laboratory reference manuals. However, these manuals are readily available and Applicants can supply such copies at the Examiner's request.

- CC** Ausubel et al., eds., *Current Protocols in Molecular Biology*, Green Publishing Assoc., Inc. and Wiley & Sons, Inc., NY (1994).
- ER** *Remington's Pharmaceutical Sciences*, 18th Ed., A. R. Gennaro, ed., Mack Publishing Co., Easton, PA 18042 (1990).
- ES** Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2d Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989).
- EZ** Stewart and Young, *Solid Phase Peptide Synthesis*, Pierce Chem. Co., Rockford, IL (1984).

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

5/28/98
Date
Signature


The information disclosure statement submitted herewith has been filed to the best of Applicants' knowledge before the mailing date of a first Office action on the merits per 37 CFR 1.97(b).

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen, Inc. An original and one copy of this paper are enclosed.

Please send all future correspondence to:
U.S. Patent Operations/NAO
M/S 10-1-B
AMGEN INC.
Amgen Center
1840 De Havilland Drive
Thousand Oaks, California 91320-1789

Respectfully submitted,



Nancy A. Oleski
Attorney/Agent for Applicant(s)
Registration No.: 34,688
Phone: (805) 447-6504
Date: May 26, 1998